SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the validation of its first multimodal artificial intelligence (MMAI) digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence (BCR). Researchers successfully trained and validated the model for patients who experience BCR after radical prostatectomy surgery, which is strongly associated with the risk of the disease spreading. The data was presented by Dr. Todd Morgan from Michigan Medicine as an oral presentation at the 2024 AUA Annual Meeting, on Sunday, May 5, 2024. A radical prostatectomy is the removal of the prostate in a patient with prostate cancer and has served as a primary treatment for this disease for many years. However, about 20-40% of patients who undergo the procedure eventually develop BCR, which is an indicator of the cancer returning

ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, today announced its continued work with Movember, the leading charity changing the face of men's health on a global scale.

SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, today announced its continued work with Movember, the leading charity changing the face of men's health on a global scale. “We are privileged to stand shoulder to shoulder with industry leaders in the battle against prostate cancer,” said Andre Esteva, CEO and co-founder of ArteraAI. “It is through strategic collaborations with those who share a passion for advancing how we treat this disease, that we will be able to harness AI to accelerate personalized cancer treatment.”. This announcement follows a recent study presented at the 2023 European Society for Medical Oncology Congress (ESMO). The study successfully validated ArteraAI's prognostic model in advanced prostate cancer, demonstrating stronger prognostic correlations than individual clinical factors. This study was a component of the broader STRATOSPHere project, initiated and funded by Movember and Prostate Cancer UK, an initiative to accelerate the progress of precision medicine by using data from tumor and blood samples of men participating in STAMPEDE, to identify biomarker-treatment pairings to personalize therapy